Based on these findings, it is suggested that low doses of bortezomib inhibit colitis, but in high doses of bortezomib, excessive suppression of NF-κB disrupts the proliferation of intestinal epithelial cells and leads to aggravation of colitis. Here, NFKB1 is linked to colitis.